Dr. Dorff Discusses the Use of PARP Inhibitors in Prostate Cancer
June 11th 2019Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.
Read More
Dr. Dorff on PARP Inhibitors in Prostate Cancer
March 7th 2019Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the use of PARP inhibitors in prostate cancer.
Read More
Dr. Dorff on Sequencing in Metastatic Castration-Resistant Prostate Cancer
February 12th 2019Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses sequencing in metastatic castration-resistant prostate cancer (mCRPC).
Read More
Dr. Dorff on the Status of Immunotherapy in Prostate Cancer
February 1st 2019Tanya B. Dorff, MD, associate clinical professor in the Department of Medical Oncology and Therapeutics Research, and head of the genitourinary cancers program at City of Hope, discusses the status of immunotherapy in prostate cancer.
Read More
Dr. Dorff on Choosing Between Therapies in Nonmetastatic CRPC
January 24th 2019Tanya B. Dorff, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, head, Genitourinary Cancers Program, City of Hope, discusses choosing between therapies in nonmetastatic castration-resistant prostate cancer.
Read More